Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

bluebird bio to Spin Off Its Oncology Business

By Cory Renauer - Jan 11, 2021 at 11:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech will then focus on its rare disease programs.

A biotech that has been developing new treatments for cancer and cures for severe genetic diseases will soon become a pair of more-focused independent companies. On Monday, bluebird bio ( BLUE 0.60% ) announced its intent to spin off its oncology business.

The transition is expected to take place this year. The rare disease treatment portfolio will remain with bluebird bio, and the current president of that segment of the company, Andrew Obenshain, will become its CEO. Nick Leschly, bluebird bio's current CEO, will take the helm of the spin-off, currently being called Oncology Newco.

Life sciences laboratory

Image source: Getty Images.

Bluebird won't have any trouble convincing investors it needs to focus more closely on its programs for severe genetic diseases. About a year and a half ago, the European Commission granted conditional marketing approval for Zynteglo as a gene-therapy treatment for certain patients with transfusion-dependent beta-thalassemia. An unfortunately slow commercial launch, though, has limited total revenue to less than 10% of bluebird bio's research and development budget.

In November, bluebird disclosed that the FDA had requested more information regarding Zynteglo's manufacturing process as it transitions from clinical trials to commercial-stage production. This will probably keep the company from submitting its FDA application until late 2022.

In partnership with Bristol Myers Squibb ( BMY 0.91% ), Oncology Newco could launch ide-cel this spring for multiple myeloma patients who have run out of treatment options. In September, the FDA began a priority review that should be a slam dunk. During a clinical trial supporting the application, treatment with ide-cel shrank tumors for 73% of patients and helped 33% achieve complete remission.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$10.01 (0.60%) $0.06
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$56.83 (0.91%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.